title: Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy.
abstract: OBJECTIVE
  The purpose of this study was to assess if microvolt T-wave alternans (MTWA) is an independent predictor of mortality in patients with ischemic cardiomyopathy.
  
  
  BACKGROUND
  Microvolt T-wave alternans has been proposed as an effective tool for identifying high-risk patients with ischemic cardiomyopathy who are likely to benefit from implantable cardioverter-defibrillator (ICD) therapy. However, earlier studies have been limited in their ability to control for baseline differences between MTWA-negative and -non-negative (positive and indeterminate) patients.
  
  
  METHODS
  We enrolled 768 consecutive patients with ischemic cardiomyopathy (left ventricular ejection fraction < or =35%) and no prior history of ventricular arrhythmia. All patients underwent baseline MTWA testing and were classified as MTWA negative or non-negative. Multivariable Cox regression analyses, stratified by ICD status, were used to determine the association between MTWA testing and mortality after adjusting for demographic, clinical, and treatment differences between MTWA-negative and -non-negative patients.
  
  
  RESULTS
  We identified 514 (67%) patients with a non-negative MTWA test. After multivariable adjustment, a non-negative MTWA test was associated with a significantly higher risk for all-cause (stratified hazard ratio [HR] = 2.24 [95% confidence interval 1.34 to 3.75]; p = 0.002) and arrhythmic mortality (stratified HR = 2.29 [1.00 to 5.24]; p = 0.049) but not for nonarrhythmic mortality (stratified HR = 1.77 [0.84 to 3.74]; p = 0.13). In subgroup analyses, a non-negative MTWA test was also associated with a higher risk for all-cause mortality in patients with ejection fractions < or =30% (stratified HR = 2.10 [1.18 to 3.73]; p = 0.01) and after excluding those with indeterminate MTWA tests (stratified HR = 2.08 [1.18 to 3.66]; p = 0.01).
  
  
  CONCLUSIONS
  Microvolt T-wave alternans is a strong and independent predictor of all-cause and arrhythmic mortality in patients with ischemic cardiomyopathy.
authors: The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart & Vascular Center, Cincinnati, Ohio, USA.
authors: Theodore
authors: T
authors: Chow
authors: Dean J
authors: DJ
authors: Kereiakes
authors: Cheryl
authors: C
authors: Bartone
authors: Terri
authors: T
authors: Booth
authors: Edward J
authors: EJ
authors: Schloss
authors: Theodore
authors: T
authors: Waller
authors: Eugene S
authors: ES
authors: Chung
authors: Santosh
authors: S
authors: Menon
authors: Brahmajee K
authors: BK
authors: Nallamothu
authors: Paul S
authors: PS
authors: Chan